• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

房颤中的多种合并症和共病及其对生存的影响:来自英国生物库队列的研究结果。

Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort.

机构信息

General Practice and Primary Care, Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

出版信息

Europace. 2018 Nov 1;20(FI_3):f329-f336. doi: 10.1093/europace/eux322.

DOI:10.1093/europace/eux322
PMID:29112751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6277149/
Abstract

AIMS

To examine the number and type of co-morbid long-term health conditions (LTCs) and their associations with all-cause mortality in an atrial fibrillation (AF) population.

METHODS AND RESULTS

Community cohort participants (UK Biobank n = 502 637) aged 37-73 years were recruited between 2006 and 2010. Self-reported LTCs (n = 42) identified in people with AF at baseline. All-cause mortality was available for a median follow-up of 7 years (interquartile range 76-93 months). Hazard ratios (HRs) examined associations between number and type of co-morbid LTC and all-cause mortality, adjusting for age, sex, socio-economic status, smoking, and anticoagulation status. Three thousand six hundred fifty-one participants (0.7% of the study population) reported AF; mean age was 61.9 years. The all-cause mortality rate was 6.7% (248 participants) at 7 years. Atrial fibrillation participants with ≥4 co-morbidities had a six-fold higher risk of mortality compared to participants without any LTC. Co-morbid heart failure was associated with higher risk of mortality [HR 2.96, 95% confidence interval (CI) 1.83-4.80], whereas the presence of co-morbid stroke did not have a significant association. Among non-cardiometabolic conditions, presence of chronic obstructive pulmonary disease (HR 3.31, 95% CI 2.14-5.11) and osteoporosis (HR 3.13, 95% CI 1.63-6.01) was associated with a higher risk of mortality.

CONCLUSION

Survival in middle-aged to older individuals with self-reported AF is strongly correlated with level of multimorbidity. This group should be targeted for interventions to optimize their management, which in turn may potentially reduce the impact of their co-morbidities on survival. Future AF clinical guidelines need to place greater emphasis on the issue of co-morbidity.

摘要

目的

在房颤(AF)人群中,检查合并的长期健康状况(LTC)的数量和类型及其与全因死亡率的关系。

方法和结果

社区队列参与者(英国生物库 n = 502637)年龄在 37-73 岁之间,于 2006 年至 2010 年期间招募。在基线时患有 AF 的人群中自我报告了 LTC(n = 42)。在中位数为 7 年(四分位距 76-93 个月)的随访期间,可获得全因死亡率。风险比(HRs)检查了合并 LTC 的数量和类型与全因死亡率之间的关系,调整了年龄、性别、社会经济地位、吸烟和抗凝状态。3651 名参与者(研究人群的 0.7%)报告了 AF;平均年龄为 61.9 岁。7 年后,全因死亡率为 6.7%(248 名参与者)。与没有任何 LTC 的参与者相比,患有≥4 种合并症的 AF 参与者的死亡率高 6 倍。合并心力衰竭与更高的死亡率相关[HR 2.96,95%置信区间(CI)1.83-4.80],而合并中风则没有显著相关性。在非心血管代谢疾病中,慢性阻塞性肺疾病(HR 3.31,95%CI 2.14-5.11)和骨质疏松症(HR 3.13,95%CI 1.63-6.01)的存在与更高的死亡率相关。

结论

自我报告的 AF 中中年至老年个体的生存与合并症的严重程度密切相关。该人群应成为干预措施的目标,以优化其管理,从而可能降低其合并症对生存的影响。未来的 AF 临床指南需要更加重视合并症问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f5d/6277149/f09b2e5cd15f/eux322f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f5d/6277149/0b05a0030728/eux322f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f5d/6277149/f09b2e5cd15f/eux322f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f5d/6277149/0b05a0030728/eux322f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f5d/6277149/f09b2e5cd15f/eux322f2.jpg

相似文献

1
Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort.房颤中的多种合并症和共病及其对生存的影响:来自英国生物库队列的研究结果。
Europace. 2018 Nov 1;20(FI_3):f329-f336. doi: 10.1093/europace/eux322.
2
Association between cardiometabolic comorbidity and mortality in patients with atrial fibrillation.心房颤动患者心脏代谢合并症与死亡率之间的关联。
BMC Cardiovasc Disord. 2025 Apr 30;25(1):344. doi: 10.1186/s12872-025-04784-8.
3
Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort.多病症、人口因素与死亡率之间的关系:来自英国生物银行队列研究的发现。
BMC Med. 2019 Apr 10;17(1):74. doi: 10.1186/s12916-019-1305-x.
4
Role of primary and secondary care data in atrial fibrillation ascertainment: impact on risk factor associations, patient management, and mortality in UK Biobank.初级和二级医疗数据在心房颤动确诊中的作用:对英国生物银行中危险因素关联、患者管理及死亡率的影响
Europace. 2025 Feb 5;27(2). doi: 10.1093/europace/euae291.
5
Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: a study of 5658 UK Biobank participants.类风湿关节炎的多种共病模式及其对不良结局的影响:对 5658 名英国生物库参与者的研究。
BMJ Open. 2020 Nov 23;10(11):e038829. doi: 10.1136/bmjopen-2020-038829.
6
Associations between multimorbidity and adverse health outcomes in UK Biobank and the SAIL Databank: A comparison of longitudinal cohort studies.英国生物银行和 SAIL 数据库中多重疾病与不良健康结局的关联:纵向队列研究的比较。
PLoS Med. 2022 Mar 7;19(3):e1003931. doi: 10.1371/journal.pmed.1003931. eCollection 2022 Mar.
7
The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.移动医疗技术支持路径对合并多种疾病患者心房颤动相关不良事件的影响:mAFA-II 随机临床试验。
JAMA Netw Open. 2021 Dec 1;4(12):e2140071. doi: 10.1001/jamanetworkopen.2021.40071.
8
Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort.英国生物库队列中的多病共存、多种药物并用和 COVID-19 感染。
PLoS One. 2020 Aug 20;15(8):e0238091. doi: 10.1371/journal.pone.0238091. eCollection 2020.
9
Burden of cardiometabolic disorders and lifetime risk of new-onset atrial fibrillation among men and women: the Rotterdam Study.心血管代谢疾病负担与新发心房颤动的终身风险:鹿特丹研究。
Eur J Prev Cardiol. 2024 Jul 23;31(9):1141-1149. doi: 10.1093/eurjpc/zwae045.
10
Characteristics and 12-month outcome of patients with atrial fibrillation at a tertiary hospital in Botswana.博茨瓦纳一家三级医院心房颤动患者的特征及12个月的预后情况
Cardiovasc J Afr. 2019;30(3):168-173. doi: 10.5830/CVJA-2019-013. Epub 2019 Mar 27.

引用本文的文献

1
Hospital healthcare utilisation in patients with atrial fibrillation: the role of multimorbidity and age.心房颤动患者的医院医疗服务利用情况:共病和年龄的作用。
Neth Heart J. 2025 Jul 18. doi: 10.1007/s12471-025-01968-x.
2
Robustly measuring multimorbidity using disparate linked datasets.使用不同的关联数据集稳健地测量多种疾病并存情况。
Commun Med (Lond). 2025 Jul 8;5(1):283. doi: 10.1038/s43856-025-00995-4.
3
Patients' experiences of atrial fibrillation and comorbidity management in clinical practice: a pan-European qualitative descriptive interview study.

本文引用的文献

1
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry.心房颤动合并癌症病史患者的管理和结局:ORBIT-AF 登记研究。
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192-197. doi: 10.1093/ehjqcco/qcx004.
2
Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.多重疾病与心房颤动患者住院及死亡风险:一项基于人群的研究。
Am Heart J. 2017 Mar;185:74-84. doi: 10.1016/j.ahj.2016.11.008. Epub 2016 Dec 9.
3
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
患者在临床实践中对心房颤动及合并症管理的体验:一项泛欧洲定性描述性访谈研究
BMJ Open. 2025 Jun 16;15(6):e094839. doi: 10.1136/bmjopen-2024-094839.
4
Multimorbidity increases risk of cardiovascular outcomes in permanent atrial fibrillation: Data from the RACE II study.多种疾病共患增加永久性心房颤动患者发生心血管事件的风险:来自RACE II研究的数据。
Int J Cardiol Heart Vasc. 2025 Apr 24;59:101686. doi: 10.1016/j.ijcha.2025.101686. eCollection 2025 Aug.
5
Association between cardiometabolic comorbidity and mortality in patients with atrial fibrillation.心房颤动患者心脏代谢合并症与死亡率之间的关联。
BMC Cardiovasc Disord. 2025 Apr 30;25(1):344. doi: 10.1186/s12872-025-04784-8.
6
Healthcare Expenditure on Atrial Fibrillation in the United States: The Medical Expenditure Panel Survey 2016 to 2021.美国心房颤动的医疗保健支出:2016年至2021年医疗支出面板调查
JACC Adv. 2025 May;4(5):101716. doi: 10.1016/j.jacadv.2025.101716. Epub 2025 Apr 25.
7
Health conditions in adults with atrial fibrillation compared with the general population: a population-based cross-sectional analysis.与普通人群相比,成人房颤患者的健康状况:一项基于人群的横断面分析。
Heart. 2025 Mar 4. doi: 10.1136/heartjnl-2024-324618.
8
Multimorbidity Is Associated With Symptom Severity and Disease Progression in Patients with Paroxysmal Atrial Fibrillation-Data From the RACE V Study.多重疾病与阵发性心房颤动患者的症状严重程度和疾病进展相关——来自RACE V研究的数据。
J Am Heart Assoc. 2025 Mar 4;14(5):e034514. doi: 10.1161/JAHA.123.034514. Epub 2025 Feb 26.
9
Association of single and multiple cardiometabolic diseases with atrial fibrillation: a prospective cohort study.单一及多种心脏代谢疾病与心房颤动的关联:一项前瞻性队列研究。
Open Heart. 2025 Feb 23;12(1):e003034. doi: 10.1136/openhrt-2024-003034.
10
Multimorbidity in patients with atrial fibrillation and community controls: A population-based study.心房颤动患者与社区对照人群的多重疾病:一项基于人群的研究。
J Multimorb Comorb. 2024 Dec 21;14:26335565241310281. doi: 10.1177/26335565241310281. eCollection 2024 Jan-Dec.
慢性阻塞性肺疾病对心房颤动预后的影响:欧洲观察性研究计划心房颤动试点调查(EORP-AF)总登记处的报告
Am Heart J. 2016 Nov;181:83-91. doi: 10.1016/j.ahj.2016.08.011. Epub 2016 Aug 27.
4
Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.心房颤动与心血管疾病、肾脏疾病和死亡风险:系统评价和荟萃分析。
BMJ. 2016 Sep 6;354:i4482. doi: 10.1136/bmj.i4482.
5
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Europace. 2016 Nov;18(11):1609-1678. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.
6
Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.心房颤动患者的死亡原因和影响因素。
Am J Med. 2016 Dec;129(12):1278-1287. doi: 10.1016/j.amjmed.2016.06.045. Epub 2016 Jul 28.
7
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.新诊断房颤患者的两年结局:来自GARFIELD-AF研究的结果
Eur Heart J. 2016 Oct 7;37(38):2882-2889. doi: 10.1093/eurheartj/ehw233. Epub 2016 Jun 29.
8
Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study.基层医疗中房颤、抗凝治疗、脑血管事件风险与多种疾病并存之间的关联:一项基于注册登记的研究
BMC Cardiovasc Disord. 2016 Mar 28;16:61. doi: 10.1186/s12872-016-0235-1.
9
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.非瓣膜性心房颤动抗凝治疗患者的死亡原因及全因死亡率预测因素:来自ROCKET AF研究的数据
J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.
10
Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study.2012年法国医院收治的房颤患者的死亡原因:一项全国性数据库研究
Open Heart. 2015 Dec 1;2(1):e000290. doi: 10.1136/openhrt-2015-000290. eCollection 2015.